Heres How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years - Investing.com UK
| A1SN34 Stock | BRL 54.00 5.16 10.57% |
About 55% of Ascendis Pharma's investors are presently thinking to get in. The analysis of current outlook of investing in Ascendis Pharma AS suggests that some traders are interested regarding Ascendis Pharma's prospects. The current market sentiment, together with Ascendis Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Ascendis Pharma AS stock news signals to limit their universe of possible portfolio assets.
Ascendis |
Heres How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years Investing.com UK
Read at news.google.com
 |
Ascendis Pharma Fundamental Analysis
We analyze Ascendis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascendis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascendis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Ascendis Pharma is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Ascendis Pharma AS Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ascendis Pharma stock to make a market-neutral strategy. Peer analysis of Ascendis Pharma could also be used in its relative valuation, which is a method of valuing Ascendis Pharma by comparing valuation metrics with similar companies.
Peers
Ascendis Pharma Related Equities
| CAON34 | Capital One | 1.81 | ||||
| L1YG34 | Lloyds Banking | 0.89 | ||||
| T1TW34 | Take Two | 0.76 | ||||
| U1RI34 | United Rentals | 0.66 | ||||
| W1MG34 | Warner Music | 0.64 | ||||
| A1GI34 | Agilent Technologies | 0.00 | ||||
| G2DI33 | G2D Investments | 1.38 |
Complementary Tools for Ascendis Stock analysis
When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |